NCT06415669View on ClinicalTrials.gov

A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 19, 2024

Primary Completion Date

May 19, 2026

Study Completion Date

May 19, 2027

Conditions
Gastric/Gastroesophageal Junction Adenocarcinoma
Interventions
DRUG

Paclitaxel for injection (albumin-bound)

100 mg/m2, day 1, day 8, every 21 days for a cycle.

DRUG

Adebrelimab

20mg/kg or 1200mg, the first day, every 21 days as a cycle.

DRUG

Apatinib mesylate

250mg once a day for 5 consecutive days and discontinue for 2 days

Trial Locations (1)

Unknown

RECRUITING

The First Affiliated Hospital of Xiamen University, Fuzhou

All Listed Sponsors
lead

The First Affiliated Hospital of Xiamen University

OTHER